Finding Gold In An Unfavored Space: Servier And MicroRNA Start Up Miragen In CV Deal

Starting with a $45 million upfront, the potential value of this deal, which centers on three pre-clinical cardiovascular targets, could reach up to $1 billion, if the companies meet regulatory and commercial milestones.